GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Synonyms: AMG 410 | AMG-410 | example 99 [WO2024107686]
Compound class:
Synthetic organic
Comment: AMG410 is a pan-KRAS allosteric inhibitor, with activity at common oncogenic mutant KRAS proteins (e.g. KRASG12D/V, KRASG13D) [1]. It has ~100-fold lower inhibitory potency at HRAS and NRAS, and can bind both GTP- and GDP-bound KRAS [2].
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Bauer A, Amegadzie A, Smaligo A, Wigman B, Lanman BA, Mohr C, Emmetiere F, Stellwagen JC, Medina JH, Pettus LH et al.. (2024)
Macrocyclic KRAS inhibitors and methods of use. Patent number: WO2024107686A1. Assignee: Amgen Inc.. Priority date: 14/11/2023. Publication date: 23/05/2024. |
2. Lanman BA, Wurz RP, Verma R, Osgood T, Gaida K, Mohn D, Chen YC, Diaz G, Saiki AY et al..
ND01 - AMG 410: An H/NRAS-sparing pan-KRAS inhibitor with dual GTP(on)/GDP(off)-state activity for the treatment of diverse KRAS-mutant tumors. Accessed on 20/08/2025. Modified on 20/08/2025. abstractsonline.com, https://www.abstractsonline.com/pp8/#!/20273/presentation/7352 |